The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.
COVID-19
SARS-CoV-2
antivirals
clinical trials
drug development
immunomodulators
research protocols
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
04
2020
accepted:
01
09
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this disease currently relies on supportive care and the off-label and compassionate use of antivirals and immunomodulators. Nevertheless, there has been a great worldwide effort to progress research and test the efficacy and safety/tolerability profiles of numerous candidate agents that may positively affect the various clinical syndromes associated with COVID-19. In parallel, vaccination and chemoprophylaxis strategies are being investigated. This article provides a summary of interventional studies targeting COVID-19 during the emergency phase of the outbreak to broadly inform clinicians and researchers on what happened and what they can expect in upcoming months. The clinicaltrials.gov database and the European Union (EU) Clinical Trials Register were investigated on March 31, 2020, to identify all ongoing phase 1-4 research protocols testing pharmacological interventions targeting SARS-CoV-2 infection and/or clinical syndromes associated with COVID-19. Overall, six phase 1, four phase 1-2, 14 phase 2, ten phase 2-3, 19 phase 3, and nine phase 4 studies were identified, and the features of these studies are described in the present review. We also provide an updated overview of the change overtime in the pipeline following this emergency phase and based on the current epidemiology of the COVID-19 pandemic.
Identifiants
pubmed: 33072781
doi: 10.3389/fmed.2020.552991
pmc: PMC7542224
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
552991Informations de copyright
Copyright © 2020 Canevelli, Remoli, Trentin, Riccardi, Tariciotti, Risoleo, Ancidoni, Bruno, Cesari, Vanacore and Raparelli.
Références
Ann Intern Med. 2020 Oct 20;173(8):623-631
pubmed: 32673060
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Apr 30;382(18):e41
pubmed: 32212516
Wellcome Open Res. 2020 Apr 2;5:60
pubmed: 32292826
Lancet. 2020 Apr 25;395(10233):1322-1325
pubmed: 32247324
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
N Engl J Med. 2020 May 27;:
pubmed: 32459919
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Cell Dev Biol. 2020 Jul 10;8:616
pubmed: 32754599
JAMA. 2020 May 12;323(18):1839-1841
pubmed: 32215647
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486